Last reviewed · How we verify
NCT06231862: GEODESIC
Gene Expression Objective Definition of Early Sepsis In Children
trial testing SeptiCyte (various) in Sepsis in 100 participants. Completed in 1 March 2023.
1 March 2023
Quick facts
| Lead sponsor | Seattle Children's Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 1 March 2019 |
| Primary completion | 1 March 2023 |
| Estimated completion | 1 March 2023 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- SeptiCyte (various)
Conditions studied
- Sepsis — all drugs for Sepsis →
- Non-Infectious Systemic Inflammatory Response Syndrome — all drugs for Non-Infectious Systemic Inflammatory Response Syndrome →
Sponsor
Seattle Children's Hospital
Who can join
Adults 1 Month to 17, any sex, with Sepsis or Non-Infectious Systemic Inflammatory Response Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
GEODESIC is a prospective descriptive cohort investigation that will examine the generalizability of the novel host gene expression biomarkers, SeptiCyteTM LAB, SeptiCyteTM VIRUS, SeptiCyteTM BACT, and SeptiCyteTM TRIAGE (collectively 18 genes or SeptiCyteTM LVBT) and SeptiCyteTM RAPID, for differentiating children with bacterial sepsis, versus severe viral illness, versus non-infectious related systemic inflammatory response syndrome.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06231862
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Sepsis
Currently open trials in the same condition.
- NCT07507877 — Infraclavicular Axillary Vein Collapsibility Index as a Predictor of Fluid Responsiveness · recruiting
- NCT07154615 — Assessing Immune Dysfunction in Sepsis · recruiting
- NCT07419802 — OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study · recruiting
- NCT07351344 — African Survey on Sepsis Knowledge (ASK) · recruiting
- NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting
Other Seattle Children's Hospital trials
Trials by the same sponsor.
- NCT07522112 — Evaluating a Shared Decision-making Intervention for Families About Firearm Storage · NA · not yet recruiting
- NCT06864611 — Evaluating Huddles as a Novel Approach to Improving Concussion Safety · NA · not yet recruiting
- NCT07424157 — Long-Term Follow-Up of Subjects Treated With Seattle Children's Therapeutics Gene Therapy Products · not yet recruiting
- NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting
- NCT07097792 — Concussion Recovery and Support Program · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06231862 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Seattle Children's Hospital
- Last refreshed: 30 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06231862.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing